Stephens cut shares of Catalent (NYSE:CTLT) from an overweight rating to an equal weight rating in a report released on Tuesday, Marketbeat Ratings reports.
A number of other research firms also recently issued reports on CTLT. BidaskClub downgraded Catalent from a buy rating to a hold rating in a report on Tuesday, November 14th. First Analysis started coverage on Catalent in a report on Friday, January 5th. They issued an equal weight rating for the company. Zacks Investment Research upgraded Catalent from a hold rating to a strong-buy rating and set a $49.00 price objective for the company in a report on Thursday, October 26th. Needham & Company LLC reiterated a hold rating on shares of Catalent in a report on Monday, October 23rd. Finally, ValuEngine downgraded Catalent from a buy rating to a hold rating in a report on Friday, December 1st. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $45.60.
Catalent (CTLT) opened at $40.58 on Tuesday. The company has a quick ratio of 2.49, a current ratio of 2.22 and a debt-to-equity ratio of 2.66. The stock has a market capitalization of $5,496.73, a price-to-earnings ratio of 25.77, a price-to-earnings-growth ratio of 2.40 and a beta of 1.47. Catalent has a twelve month low of $27.48 and a twelve month high of $47.87.
In other news, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction that occurred on Tuesday, November 21st. The stock was acquired at an average price of $39.22 per share, with a total value of $294,150.00. The disclosure for this purchase can be found here. 1.70% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTLT. Zions Bancorporation bought a new stake in Catalent in the 3rd quarter worth about $100,000. First Bank & Trust increased its holdings in Catalent by 54.2% in the 4th quarter. First Bank & Trust now owns 3,764 shares of the company’s stock worth $155,000 after buying an additional 1,323 shares in the last quarter. Fortaleza Asset Management Inc. bought a new stake in Catalent in the 3rd quarter worth about $164,000. Advisor Group Inc. increased its holdings in Catalent by 1.3% in the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after buying an additional 65 shares in the last quarter. Finally, CAPROCK Group Inc. bought a new stake in Catalent in the 4th quarter worth about $203,000. Institutional investors own 98.86% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Catalent (CTLT) Downgraded to “Equal Weight” at Stephens” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://sportsperspectives.com/2018/02/09/catalent-ctlt-downgraded-to-equal-weight-at-stephens.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.